September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11
Diana A Gorog
ESC guidelines and differences between NOACs Following the roll-out of the novel oral anticoagulants (NOACs), the European Society of Cardiology (ESC) published in 2012 a focused update of its guidelines for the management of atrial fibrillation (AF). Since the NOACs tested in clinical trials all showed at least non-inferiority when compared with vitamin K antagonists (VKAs), with a better safety profile, particularly with reduction in intracranial haemorrhage (ICH), the ESC 2012 guideline recommended NOACs as broadly preferable to VKAs in the vast majority of patients with non-valvular AF (NVAF).1 In 2013, the European Heart Rhythm Associati
September 2007 Br J Cardiol 2007;14:215-218
Jonathan M Morrell, George C Kassianos
As with the global results, there was a high use of evidence-based therapies in the UK patients. Despite this, the combined incidence of cardiovascular events at one year (cardiovascular death, myocardial infarction, stroke) was high at 4.82%, 4.46% and 4.35% respectively for peripheral arterial disease (PAD), cerebrovascular disease (CVD) and coronary artery disease (CAD). These figures increase markedly when hospitalisations are taken into account, particularly in patients with PAD (18.54%) compared with CVD (8.29%) and CAD (10.07%). Cardiovascular event rates increased significantly with the number of symptomatic locations (p=0.0043), incr
May 2007 Br J Cardiol 2007;14:153-59
Jonathan M Morrell, George C Kassianos For The Reach Registry Investigators
No content available
March 2007 Br J Cardiol 2007;14:90-7
Roxy Senior, John Chambers
No content available
January 2005 Br J Cardiol 2005;12:50-2
Fiona Taylor, Andrew Beswick, Jackie Victory, Karen Rees, Ingolf Griebsch, Robert West, Rod Taylor, Jackie Brown, Margaret Burke, Shah Ebrahim
No content available
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits